Results of the intention-to-treat analysis of end points after 30 months' median follow-up
End point . | CVP, n = 159 . | R-CVP, n = 162 . |
|---|---|---|
| Median time to progression, mos† | 15 | 32 |
| Events, no. (%)* | 115 (72) | 77 (48) |
| Progressive disease | 25 (16) | 16 (10) |
| Relapse after response | 85 (54) | 60 (37) |
| Death from any cause | 5 (3) | 1 (1) |
| Tumor responses, no. (%)† | ||
| Complete response | 12 (8) | 49 (30) |
| Complete response, unconfirmed | 4 (3) | 17 (11) |
| Partial response | 74 (47) | 65 (40) |
| CR + CRu + PR | 90 (57) | 131 (81) |
| Stable disease | 33 (21) | 12 (7) |
| Progressive disease | 31 (20) | 17 (11) |
| Could not be assessed | 5 (3) | 2 (1) |
| Median time to treatment failure, mos† | 7 | 27 |
| Median duration of response, mos† | 14 | 35 |
| Median disease-free survival, mos‡ | 21 | Not reached |
| Median time to new antilymphoma treatment or death, mos | 12 | Not reached |
| KM estimates for overall survival at 30 mos, %§ | 85 | 89 |
End point . | CVP, n = 159 . | R-CVP, n = 162 . |
|---|---|---|
| Median time to progression, mos† | 15 | 32 |
| Events, no. (%)* | 115 (72) | 77 (48) |
| Progressive disease | 25 (16) | 16 (10) |
| Relapse after response | 85 (54) | 60 (37) |
| Death from any cause | 5 (3) | 1 (1) |
| Tumor responses, no. (%)† | ||
| Complete response | 12 (8) | 49 (30) |
| Complete response, unconfirmed | 4 (3) | 17 (11) |
| Partial response | 74 (47) | 65 (40) |
| CR + CRu + PR | 90 (57) | 131 (81) |
| Stable disease | 33 (21) | 12 (7) |
| Progressive disease | 31 (20) | 17 (11) |
| Could not be assessed | 5 (3) | 2 (1) |
| Median time to treatment failure, mos† | 7 | 27 |
| Median duration of response, mos† | 14 | 35 |
| Median disease-free survival, mos‡ | 21 | Not reached |
| Median time to new antilymphoma treatment or death, mos | 12 | Not reached |
| KM estimates for overall survival at 30 mos, %§ | 85 | 89 |